Company
Our mission is
to contribute to well-being of humanity by treating chronic immune diseases through peptide drugs we discover and develop.
Thank you for visiting our website.
KINE SCIENCES is a company that develops ultra-small peptide innovative medicines
based on functional immunomics.
We discovered the function of a novel cytokine ERDR1 for the first time in the world
and since we have been developing drug candidates of ultra-small peptide with private
and public funding including the one from Korea Drug Development Fund for
consecutive four years.
The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis,
inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease,
and many rare immune diseases.
Though we live in an era when we see more research on life sciences and more drugs
on the market than any other era of human history, we humans have yet to find cures
for these chronic immune diseases by seeing occurrence of resistance or relapse which
make lifelong treatment of expensive medicines inevitable for patients.
These diseases put a great burden not only on patients themselves but their families
and the society as a whole.
KINE SCIENCES is committed to treating chronic immune diseases, making lives of
patients and their families better, and ultimately improving well-being of humanity by
developing safer, more economical and more convenient medicines of ultra small
peptides.
Please give us encouragement and support for our daunting journey.
Founder/CTO
-
Dae Ho Cho Ph.D
-
-
Ph.D, Chicago Medical School; B.S., SUNY
Professor of Convergence Research Institute, Korea University
Head of Nano Bio material Research Center, Korea University
Professor of Department of Life Sciences, Sookmyung Women's University
Executive
- CEO
- Hee Kyung Kim MBA
-
M.S, Business Administration, Sogang University, Bachelor of Pharmacy, Seoul National University
Senior Vice President, Head of Clinical Science Division & Regulatory Affairs Team, Samsung Bioepis
Vice President, Strategic Business Development, Samsung Electronics
Executive Director, Head of Market Access Division & Compliance, Novartis, Pharma
Manager, Regulatory Affairs, Baxter
- CFO
- Seung Bo Moon CPA
-
B.S., Business Administration, Korea University
CFO and COO of Hanel
CFO of Meere Company
CPA of Samil PwC
- COO
- Byoung Jin Seo MBA
-
M.S, Business Administration, Korea University
Vice President of Strategic Planning & BD, NKMAX
General Manager of M&A, Samsung Fire & Marine
Project Manager, A.T.Kearney
Consultant, Accenture
-
Head of
Research Team - Myun Soo Kim Ph.D
-
Ph.D & B.S, Korea University
Research Professor of Institute of Convergence Science, Korea University
Research Professor for BK21PLUS Project, Korea University
Senior Researcher, Sookmyung Women’s University
-
Head of
Strategic Planning Team - Hyun Gun Song Ph.D
-
Ph.D, Chungnam National University; M.S. & B.S. Kangwon National University
Assistant Professor of Anatomy Class of Medical School, Injae University
-
Head of Research
Planning Team - Sun Young Park Ph.D
-
B.S., M.S, & Ph.D, Department of Cell Biology, Sookmyung Women's University
Senior Researcher, Sookmyung Women's University
Senior Researcher, SIS Immunology Research Center, Sookmyung Women's University
Research Professor, Sookmyung Women’s University
-
Head of
immune-neurology Team - Chang Kyu Gu Ph.D
-
B.S., Hankuk University of Foreign Studies Ph.D., Hallym University
Instructor, Massachusetts General Hospital and Harvard Medical School
Senior Scientist, Walden Biosciences
2021
-
- 09
- KINE-101A Phase 1 IND approved by US FDA
- 05
- Substance patents regarding KINE-101, KINE-201 and KINE-301 registered in US
2020
-
- 07
- Project awarded by Korea Patent Strategy Development Institute
2019
-
- 03
- Change of corporate name to KINE SCIENCES Co.,Ltd.
- 03
- R&D Center of KINE SCIENCES established
- 07
- KINE-101A GLP study initiated
- 08
- Corporate R&D Center certification acquisition
2018
-
- 10
- Established joint research institute with Korea University
- 12
- Certified by Korea Government as a Venture Company
2017
-
- 12
- Patents regarding KINE-101, KINE-201 and KINE-301 filed in major foreign conturies
2016
-
- 08
- Company founded(Bio Pep Co., Ltd.)
- 12
- Selected as a new drug development project by the Ministry of New Drug Development Project
- Mission
- Contributing to better lives of mankind
by developing innovative therapies
- Vision 2025
- Growing as a unicorn company
carrying out more than five global clinical trials with new molecules
Core Value
-
- CHALLENGE
- Pursuing the best through change and innovation
-
- FLEXIBILITY
- Being flexible and adaptable to ever-changing environment
-
- JUSTNESS
- Sticking to the principle and being honest
-
- COMMITMENT
- Being committed to common goal and vision
-
- COLLABORATION
- Moving forward hand in hand
